DE602005024192D1 - Chinazolinderivate als Phosphodiesterasehemmer zur Verwendung für die Behandlung peripherer Arterienerkrankungen - Google Patents

Chinazolinderivate als Phosphodiesterasehemmer zur Verwendung für die Behandlung peripherer Arterienerkrankungen

Info

Publication number
DE602005024192D1
DE602005024192D1 DE602005024192T DE602005024192T DE602005024192D1 DE 602005024192 D1 DE602005024192 D1 DE 602005024192D1 DE 602005024192 T DE602005024192 T DE 602005024192T DE 602005024192 T DE602005024192 T DE 602005024192T DE 602005024192 D1 DE602005024192 D1 DE 602005024192D1
Authority
DE
Germany
Prior art keywords
treatment
peripheral arterial
arterial disease
phosphodiesterase inhibitors
quinazoline derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005024192T
Other languages
English (en)
Inventor
Richard Franklin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Biopharmaceuticals Holdings Ireland Ltd
Original Assignee
Shire Biopharmaceuticals Holdings Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Biopharmaceuticals Holdings Ireland Ltd filed Critical Shire Biopharmaceuticals Holdings Ireland Ltd
Publication of DE602005024192D1 publication Critical patent/DE602005024192D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602005024192T 2004-08-04 2005-08-04 Chinazolinderivate als Phosphodiesterasehemmer zur Verwendung für die Behandlung peripherer Arterienerkrankungen Active DE602005024192D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59843204P 2004-08-04 2004-08-04

Publications (1)

Publication Number Publication Date
DE602005024192D1 true DE602005024192D1 (de) 2010-11-25

Family

ID=35839972

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005024192T Active DE602005024192D1 (de) 2004-08-04 2005-08-04 Chinazolinderivate als Phosphodiesterasehemmer zur Verwendung für die Behandlung peripherer Arterienerkrankungen

Country Status (22)

Country Link
US (1) US20060030574A1 (de)
EP (2) EP1778235A4 (de)
JP (1) JP4758993B2 (de)
CN (1) CN101014344A (de)
AT (1) ATE484278T1 (de)
AU (1) AU2005271275A1 (de)
BR (1) BRPI0513943A (de)
CA (1) CA2575512C (de)
CY (1) CY1110881T1 (de)
DE (1) DE602005024192D1 (de)
DK (1) DK1949893T3 (de)
EA (1) EA200700406A1 (de)
ES (1) ES2353848T3 (de)
HR (1) HRP20100681T1 (de)
MX (1) MX2007001513A (de)
NO (1) NO20071098L (de)
PL (1) PL1949893T3 (de)
PT (1) PT1949893E (de)
RS (1) RS51519B (de)
SI (1) SI1949893T1 (de)
WO (1) WO2006017823A2 (de)
ZA (1) ZA200701850B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021259A2 (en) * 1999-09-21 2001-03-29 Emory University Use and compositions for treating platelet-related disorders using anagrelide
US7910597B2 (en) * 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
GB0623750D0 (en) * 2006-11-28 2007-01-10 Shire Llc Substituted quinazolines
US8304420B2 (en) * 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
GB0808947D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808952D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808968D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines
GB0808967D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2732403A (en) * 1956-01-24 Chclj
US1947926A (en) * 1934-02-20 Seed grain dressings and process of
US2862966A (en) * 1958-12-02 archo
US2256999A (en) * 1939-03-08 1941-09-23 Du Pont Nitration of organic compounds
US2469695A (en) * 1946-02-02 1949-05-10 Eastman Kodak Co Nitroaminobenzene ester compounds
US2608584A (en) * 1947-03-19 1952-08-26 Nopco Chem Co Preparation of n-alkyl arylamines
US2883435A (en) * 1956-10-10 1959-04-21 Gen Aniline & Film Corp Purification of 1,2-dichloro-4-nitrobenzene
US3313854A (en) * 1961-11-20 1967-04-11 Universal Oil Prod Co Preparation of para-nitrodiphenylamines utilizing a copper oxide catalyst
USRE31617E (en) * 1972-02-04 1984-06-26 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
US3932407A (en) * 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
JPS49132019A (de) * 1973-02-26 1974-12-18
DE2400887A1 (de) * 1974-01-09 1975-08-28 Bayer Ag Verfahren zur herstellung von nitroderivaten aromatischer verbindungen
JPS5752352B2 (de) * 1974-02-28 1982-11-06
US3983119A (en) * 1974-11-06 1976-09-28 Bristol-Myers Company Process for the preparation of optionally substituted 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones
US3983120A (en) * 1974-11-06 1976-09-28 Bristol-Myers Company Process for the preparation of optionally substituted 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones
US3988340A (en) * 1975-01-23 1976-10-26 Bristol-Myers Company 6-Alkoxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones and 7-alkoxymethyl-6-[H]-1,2,3,4-tetrahydropyrimido[2,1-b]quinazolin-2-ones
JPS5251379A (en) * 1975-10-24 1977-04-25 Sumitomo Chem Co Ltd Preparation 3,4-dihydro-2(1h)-quinazoline derivates
JPS5291885A (en) * 1976-01-23 1977-08-02 Sumitomo Chem Co Ltd 3,4-dihydro-2(1h)-quinazolinone derivatives
NL7807507A (nl) * 1977-07-25 1979-01-29 Hoffmann La Roche Tricyclische verbindingen.
US4146718A (en) * 1978-04-10 1979-03-27 Bristol-Myers Company Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides
US4208521A (en) * 1978-07-31 1980-06-17 Bristol-Myers Company Process for the preparation of imidazo[2,1-b]quinazolinones
DE3065190D1 (en) * 1979-11-05 1983-11-10 Beecham Group Plc Enzyme derivatives, and their preparation
ZW16481A1 (en) * 1980-08-15 1982-03-10 Hoffmann La Roche Novel imidazoquinazoline derivatives
US4357330A (en) * 1981-07-30 1982-11-02 Bristol-Myers Company Pharmaceutical compositions
US4444777A (en) * 1981-07-30 1984-04-24 Bristol-Myers Company Pharmaceutical compositions of anagrelide and sulfinpyrazone
US4455311A (en) * 1981-08-28 1984-06-19 Hoffmann-La Roche Inc. Imidazoquinazoline derivatives which inhibit the aggregation of blood platelets, inhibit gastric secretion or have activity on the circulatory system
JPS6028979A (ja) * 1983-07-14 1985-02-14 Dai Ichi Seiyaku Co Ltd イミダゾキナゾリン類化合物
US4837239A (en) * 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4847276A (en) * 1988-09-06 1989-07-11 Merrell Dow Pharmaceuticals Inc. Treatment of thromobocytosis with 5-(4-chlorophenyl)-2,4-diemthyl-3H-1,2,4-triazole-3-thione
GB8824496D0 (en) * 1988-10-19 1988-11-23 Beecham Group Plc Process
MX21452A (es) * 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
US5043327A (en) * 1989-07-18 1991-08-27 Janssen Pharmaceutica N.V. Positive inotropic and lusitropic 3,5-dihydroimidazo[2,1-b]quinazolin-2(1H)-one derivatives, compositions and use
US5391737A (en) * 1991-05-22 1995-02-21 Egis Gyogyszergyar Process for the preparation of 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2[3H]-one
US5306709A (en) * 1991-11-15 1994-04-26 The University Of Pennsylvania Suppression of megakaryocytopoiesis by macrophage inflammatory proteins
US6024975A (en) * 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
CA2171073A1 (en) * 1995-12-04 1997-06-05 Philip C. Lang Process for the preparation of ethyl-n-(2,3 dichloro-6- nitrobenzyl) glycine
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6110471A (en) * 1996-09-13 2000-08-29 The Board Of Trustees Of The Leland Stanford Junior University Non-hormonal method of contraception
US5874437A (en) * 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
WO1999020223A2 (en) * 1997-10-20 1999-04-29 Novo Nordisk A/S Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6156753A (en) * 1997-10-28 2000-12-05 Vivus, Inc. Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6548529B1 (en) * 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
WO2001021259A2 (en) * 1999-09-21 2001-03-29 Emory University Use and compositions for treating platelet-related disorders using anagrelide
US6194420B1 (en) * 1999-11-30 2001-02-27 Roberts Laboratories Inc. 2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof
US20020004065A1 (en) * 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents
US6388073B1 (en) * 2000-07-26 2002-05-14 Shire Us Inc. Method for the manufacture of anagrelide
US20030235609A1 (en) * 2002-01-25 2003-12-25 Lautt Wilfred Wayne Use of cholinesterase antagonists to treat insulin resistance
US20030181461A1 (en) * 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
US20030114673A1 (en) * 2002-05-29 2003-06-19 Lang Philip C. 2-amino-5,6-dihalo-3,4-dihydroquinazolines with blood platelet reducing properties
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
EP1589973B2 (de) * 2003-01-23 2012-12-26 Shire Biopharmaceuticals Holdings Ireland Limited Formulierung und verfahren zur behandlung von thrombocythämie
CA2572179A1 (en) * 2004-06-23 2006-01-19 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases

Also Published As

Publication number Publication date
US20060030574A1 (en) 2006-02-09
ES2353848T3 (es) 2011-03-07
NO20071098L (no) 2007-05-03
ZA200701850B (en) 2008-08-27
EA200700406A1 (ru) 2007-08-31
AU2005271275A1 (en) 2006-02-16
JP4758993B2 (ja) 2011-08-31
EP1778235A4 (de) 2008-08-20
EP1949893A3 (de) 2008-08-20
DK1949893T3 (da) 2011-01-31
CN101014344A (zh) 2007-08-08
HRP20100681T1 (hr) 2011-01-31
RS51519B (en) 2011-06-30
SI1949893T1 (sl) 2011-02-28
CA2575512C (en) 2010-12-14
JP2008509163A (ja) 2008-03-27
PT1949893E (pt) 2011-01-04
BRPI0513943A (pt) 2008-05-20
EP1949893B1 (de) 2010-10-13
MX2007001513A (es) 2007-03-27
CY1110881T1 (el) 2015-06-10
CA2575512A1 (en) 2006-02-16
PL1949893T3 (pl) 2011-04-29
EP1949893A2 (de) 2008-07-30
WO2006017823A2 (en) 2006-02-16
WO2006017823A3 (en) 2006-05-04
EP1778235A2 (de) 2007-05-02
ATE484278T1 (de) 2010-10-15

Similar Documents

Publication Publication Date Title
DE602005024192D1 (de) Chinazolinderivate als Phosphodiesterasehemmer zur Verwendung für die Behandlung peripherer Arterienerkrankungen
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
DK1414494T3 (da) Hæmmende antistoffer af HER3-aktivitet
ATE406351T1 (de) Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
DE602007009095D1 (de) Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
TW200634012A (en) 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
BRPI0416628A (pt) uso de compostos orgánicos
EA200802054A1 (ru) Ингибиторы фермента
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
ATE504580T1 (de) Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины
DE602007011756D1 (de) Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen
DE60220512D1 (de) Verwendung von flumazenil zur herstellung eines medikaments für die behandlung von kokainabhängigkeit
ATE503476T1 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
ATE444754T1 (de) Verwendung von tyrosinkinase-inhibitoren zur behandlung inflammatorischer prozesse
ATE334980T1 (de) Verfahren zur herstellung von 2-methyl piperazine derivaten.
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
BR0307039A (pt) Compostos, em particular de derivados uréias ou ésteres do ácido haloacetamidobenzóico e sua utilização para o tratamento de doenças parasitárias
DE60219495D1 (de) Verwendung von Interleukin-18 zur Behandlung von UV-assoziierten Hautkrankheiten
ATE431348T1 (de) Thiaepothilone zur behandlung von krebserkrankungen